omh6 Antibody

What are MYH6 and MSH6 antibodies, and what cellular components do they target?

MYH6 antibodies target the myosin heavy chain 6 protein, which is primarily expressed in cardiac muscle tissue. These monoclonal antibodies are specifically designed to recognize human MYH6 and are typically manufactured at concentrations around 1.0 mg/ml .

In contrast, MSH6 antibodies target the MSH6 protein, which is a critical component of the post-replicative DNA mismatch repair system (MMR). MSH6 functions by heterodimerizing with MSH2 to form MutS alpha, which binds to DNA mismatches and initiates DNA repair processes. When bound, MutS alpha bends the DNA helix, shields approximately 20 base pairs, and recognizes single base mismatches and dinucleotide insertion-deletion loops in the DNA .

What validation techniques are typically used to confirm antibody specificity?

High-quality research antibodies undergo rigorous validation through multiple techniques. According to the information from Atlas Antibodies, their antibodies including MYH6 are validated in immunohistochemistry (IHC), immunocytochemistry/immunofluorescence (ICC-IF), and Western blotting (WB) . These validation methods ensure the antibody specifically recognizes the target protein in different experimental contexts.

The validation process typically includes positive and negative controls, tissue panels that express varying levels of the target protein, and comparison with alternative antibodies targeting the same protein. Additionally, antibody specificity can be further confirmed using genetic approaches such as knockdown or knockout models where the target protein expression is reduced or eliminated .

How do monoclonal antibodies differ from polyclonal antibodies in research applications?

Monoclonal antibodies, such as the Mouse Monoclonal Anti-MYH6 and Rabbit Recombinant Monoclonal MSH6 antibodies described in the search results, offer several distinct advantages over polyclonal antibodies in research applications .

Monoclonal antibodies are produced from a single B-cell clone, resulting in antibodies that recognize the same epitope with identical affinity. This provides exceptional specificity and reproducibility across experiments and manufacturing batches. In contrast, polyclonal antibodies are derived from multiple B-cell clones, recognizing various epitopes on the target antigen with differing affinities.

What are the common applications for MYH6 and MSH6 antibodies in basic research?

MYH6 antibodies are primarily used in cardiovascular research, particularly for studying cardiac muscle development, function, and pathology. Common applications include:

• Immunohistochemical staining of cardiac tissue sections

• Immunofluorescence imaging of cardiomyocytes

• Western blotting for quantitative analysis of MYH6 expression levels

• Investigating MYH6 involvement in cardiomyopathies and heart development

MSH6 antibodies are predominantly used in cancer research and DNA repair studies:

• Investigating DNA mismatch repair mechanisms

• Assessing MSH6 expression in tumor samples

• Studying microsatellite instability in cancer

• Examining the role of MSH6 in recognizing DNA damage and initiating repair processes

Both antibody types can be used across multiple experimental techniques that have been validated for their specific applications.

How can humanized antibodies like HuG6.3 be optimized for therapeutic applications in cancer research?

The optimization of humanized antibodies for therapeutic applications involves several sophisticated approaches as demonstrated with the G6 anti-idiotypic monoclonal antibody discussed in the research. Humanization of mouse G6 (MuG6) antibody resulted in versions with higher binding affinity and improved therapeutic potential.

The process begins with identifying critical residues in the mouse antibody that contribute to antigen binding. In the case of HuG6, researchers identified four key residues that were mutated back to the original mouse residues, including one residue in VH (Thr73) and three residues in VL (Leu4, Leu36, Glu79), creating HuG6 version 2 (HuG6.2). Additionally, they tested the contribution of threonine versus lysine at position 73 in the VH chain by making a T73K mutation, creating HuG6 version 3 (HuG6.3) .

These humanized antibodies were then thoroughly assessed for binding affinity using multiple techniques. ELISA and BIAcore analysis revealed that HuG6.2 and HuG6.3 exhibited superior binding affinity compared to the parental MuG6, with KD values of 0.23 nM and 0.16 nM respectively, versus 0.35 nM for MuG6 . This demonstrates how strategic modifications of key residues can enhance the therapeutic potential of humanized antibodies.

The optimization process must also evaluate the antibody's ability to mediate effector functions like antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which are crucial for their therapeutic efficacy in eliminating target cells .

How do somatic hypermutations affect the specificity and affinity of monoclonal antibodies in research applications?

Somatic hypermutation plays a crucial role in determining the specificity and affinity of monoclonal antibodies. Research by Wrammert et al. revealed that influenza-specific antibodies had an unusually high rate of somatic mutation: half of the flu-specific antibody-secreting cells (ASCs) had more than 20 somatic mutations, whereas only a quarter of the memory IgG+ B cells were mutated to this degree. The ratio of complementarity-determining region (CDR) to framework region (FWR) mutations was approximately 2:1 .

These somatic mutations enhance antibody affinity through a process of selection where B cells with higher-affinity receptors are preferentially expanded. This contradicts the mechanism of original antigenic sin (OAS), as the elicited antibodies showed higher affinity for the immunizing strain rather than previously encountered strains .

For research applications, understanding the pattern and extent of somatic hypermutation is critical when selecting monoclonal antibodies for specific targets. Highly mutated antibodies often demonstrate superior specificity and affinity but may recognize more restricted epitopes. When developing therapeutic antibodies or research reagents, evaluating the somatic mutation profile can provide insights into the potential specificity, cross-reactivity, and binding characteristics of the antibody .

What are the considerations for using anti-MSH6 antibodies to investigate microsatellite instability in cancer research?

When using anti-MSH6 antibodies to investigate microsatellite instability (MSI) in cancer research, several sophisticated considerations must be addressed:

• Selection of appropriate antibody format: The APC-conjugated MSH6 antibody (like ab305536) offers direct fluorescent detection capabilities, which is advantageous for flow cytometry and immunofluorescence applications investigating MSH6 expression in tumor samples .

• Understanding the molecular context: MSH6 functions in heterodimerization with MSH2 to form MutS alpha, which is essential for recognizing DNA mismatches. This complex shields approximately 20 base pairs and recognizes single base mismatches and dinucleotide insertion-deletion loops. Therefore, interpretation of MSH6 staining patterns must consider this functional interaction .

• Correlation with genetic analysis: Immunohistochemical detection of MSH6 should be correlated with genetic and molecular analyses of microsatellite regions to establish the relationship between protein expression and functional MMR deficiency.

• Tissue preparation and antigen retrieval: MSH6 is a nuclear protein, so appropriate nuclear permeabilization and antigen retrieval methods are critical for accurate detection in formalin-fixed, paraffin-embedded (FFPE) tissues.

• Quantitative analysis: For accurate assessment of MSH6 expression levels in tumor versus normal tissue, quantitative image analysis methods should be employed rather than relying solely on qualitative assessment.

These considerations ensure that anti-MSH6 antibodies are used optimally to investigate the complex relationship between MSH6 expression, MMR function, and microsatellite instability in cancer research.

How can single-cell reverse transcriptase PCR techniques enhance monoclonal antibody development from antibody-secreting cells?

Single-cell reverse transcriptase PCR (RT-PCR) techniques have revolutionized monoclonal antibody development by enabling the isolation and amplification of immunoglobulin variable regions from individual antibody-secreting cells (ASCs). Wrammert et al. demonstrated this approach by generating more than 50 specific anti-influenza monoclonal antibodies through single-cell RT-PCR of ASCs, followed by subcloning and protein production in 293A cells .

This method offers several significant advantages:

• Preservation of natural heavy and light chain pairing: Unlike display technologies that may create unnatural pairings, single-cell RT-PCR preserves the original heavy and light chain combinations that were selected during the immune response.

• Rapid isolation of high-affinity antibodies: By targeting ASCs that peak around day 7 after booster immunization, researchers can access a "pauci-clonal" population where approximately 71% of the sorted cells are antigen-specific. This significantly enriches for high-affinity antibodies that have undergone affinity maturation .

• Access to the natural mutation landscape: The technique reveals the extent of somatic hypermutation in antigen-specific antibodies. In the influenza study, half of the flu-specific ASCs had more than 20 somatic mutations, providing insights into the maturation process of the antibody response .

• Speed of development: This approach allows for the production of monoclonal antibodies in a very short time period (less than 30 days), which is particularly valuable for rapidly responding to emerging infectious diseases .

• Application to diverse targets: While initially demonstrated with influenza, this method can potentially be applied to many diseases for which human subjects can be followed up the week after a booster immunization.

For optimal implementation, researchers should carefully time the collection of blood samples to coincide with the peak ASC response (typically day 7 post-immunization), use flow cytometry to sort CD19+CD3-CD20lowCD27highCD38high cells, and employ single-cell isolation techniques to ensure one cell per reaction .

What are the optimal conditions for using MYH6 and MSH6 antibodies in different experimental techniques?

The optimal conditions for using MYH6 and MSH6 antibodies vary depending on the experimental technique:

For Immunohistochemistry (IHC):

• MYH6 antibodies: Typically require antigen retrieval (heat or enzymatic) for FFPE tissues. Optimal dilutions range from 1:100 to 1:500 depending on the specific antibody and detection system .

• MSH6 antibodies: Nuclear staining requires proper permeabilization. APC-conjugated antibodies like the anti-MSH6 [EPR20316] should be protected from light during staining procedures .

For Western Blotting (WB):

• Proper sample preparation is crucial, including appropriate lysis buffers that preserve protein structure.

• For both antibody types, typical dilutions range from 1:1000 to 1:5000.

• Blocking with 5% BSA or non-fat milk in TBST is recommended to minimize background.

• Expected molecular weights: MYH6 (~223 kDa) and MSH6 (~160 kDa).

For Immunofluorescence/ICC-IF:

• For both antibody types, fixation with 4% paraformaldehyde followed by permeabilization with 0.1-0.5% Triton X-100 is typically effective.

• Dilution ranges of 1:100 to 1:500 are commonly used.

• For MSH6, counterstaining with DAPI helps visualize nuclear localization.

• For APC-conjugated antibodies, minimize exposure to light and consider using an anti-photobleaching mounting medium .

Each technique requires optimization of antibody concentration, incubation time, and temperature to achieve optimal signal-to-noise ratio while maintaining specificity.

How can researchers validate new monoclonal antibodies against MYH6 or MSH6 proteins?

Validating new monoclonal antibodies against MYH6 or MSH6 proteins requires a multi-faceted approach:

• Specificity testing:

  • Western blot analysis using positive control samples (tissues/cells known to express the target protein) and negative controls

  • Immunoprecipitation followed by mass spectrometry to confirm the identity of the pulled-down protein

  • Testing on knockout/knockdown cell lines to confirm specificity

  • Peptide competition assays where the antibody is pre-incubated with purified antigen

• Cross-reactivity assessment:

  • Testing against closely related proteins (e.g., other myosin heavy chains for MYH6 antibodies)

  • Species cross-reactivity evaluation to determine utility across different model organisms

• Performance evaluation across multiple techniques:

  • Systematic testing in IHC, ICC/IF, flow cytometry, and WB

  • Optimization of conditions for each application

  • Comparison with established reference antibodies

• Reproducibility assessment:

  • Evaluation across different lots

  • Testing by independent laboratories

  • Statistical analysis of results to ensure consistency

• Functional validation:

  • For MSH6 antibodies, verifying detection of the MutS alpha complex through co-immunoprecipitation with MSH2

  • For MYH6 antibodies, confirming specific detection in cardiac tissues versus skeletal muscle

Following these validation steps ensures that new monoclonal antibodies meet the rigorous standards required for research applications and provides confidence in experimental results generated using these reagents .

What approaches can be used to humanize mouse monoclonal antibodies for therapeutic applications?

Humanization of mouse monoclonal antibodies involves sophisticated engineering approaches to reduce immunogenicity while preserving antigen binding. The search results illustrate several effective strategies:

The methodical approach to humanization illustrated by the G6 antibody case study provides a template for researchers developing therapeutic antibodies against MYH6, MSH6, or other targets.

How can antibody-secreting cells (ASCs) be isolated and leveraged for rapid monoclonal antibody development?

The isolation and utilization of antibody-secreting cells (ASCs) for rapid monoclonal antibody development involves a strategic approach targeting a specific cellular population:

• Timing of blood collection:
  The numbers of ASCs peak around day 7 after booster immunization in what Wrammert et al. described as a short "burst," waning rapidly thereafter. This timing is critical for efficient isolation of antigen-specific ASCs .

• Flow cytometric isolation:
  ASCs can be sorted by gating cells as CD19+CD3-CD20low and then subgating as CD27highCD38high. This phenotypic profile distinguishes early ASCs from memory B cells, which peak later (around day 14) .

• Single-cell isolation:
  Individual ASCs are isolated into separate wells to ensure clonality of the resulting antibodies.

• RT-PCR amplification of immunoglobulin genes:
  The immunoglobulin variable regions are amplified from each ASC by single-cell reverse transcriptase PCR, preserving the natural pairing of heavy and light chains .

• Cloning and expression:
  The amplified variable regions are subcloned into expression vectors with appropriate constant regions and expressed in mammalian cells (e.g., 293A cells) for antibody production .

• Screening and characterization:
  The produced antibodies are screened for antigen specificity, binding affinity, and functional activity.

This approach offers remarkable efficiency, with approximately 71% of the sorted ASCs being antigen-specific in the influenza vaccination study. Furthermore, the high rate of somatic mutation observed in these cells (>20 mutations in half of the flu-specific ASCs) indicates substantial affinity maturation, resulting in high-affinity antibodies .

The entire process can be completed in less than 30 days, making it an exceptionally rapid method for generating human monoclonal antibodies from vaccinated or immune individuals .

How can researchers address non-specific binding issues when using MYH6 or MSH6 antibodies?

Non-specific binding is a common challenge when working with antibodies. For MYH6 and MSH6 antibodies, several methodological approaches can resolve these issues:

• Optimize blocking conditions:

  • Increase blocking time (1-2 hours at room temperature or overnight at 4°C)

  • Test different blocking agents (BSA, non-fat milk, normal serum from the secondary antibody species)

  • Use commercial blocking solutions specifically designed for problematic samples

• Titrate antibody concentration:

  • Perform a dilution series to determine the optimal antibody concentration that maximizes specific signal while minimizing background

  • For fluorescently labeled antibodies like APC-conjugated MSH6, titration is especially important to achieve optimal signal-to-noise ratio

• Modify washing procedures:

  • Increase the number and duration of washes

  • Add detergents (0.1-0.3% Triton X-100 or Tween-20) to washing buffers

  • Use high-salt washes (up to 500 mM NaCl) for particularly sticky antibodies

• Include additional controls:

  • Isotype controls matched to the primary antibody

  • Secondary-only controls to assess non-specific binding of secondary antibodies

  • Absorption controls where the antibody is pre-incubated with the immunizing peptide

• Sample-specific optimizations:

  • For tissue sections, increasing the antigen retrieval time or trying alternative retrieval methods (heat vs. enzymatic)

  • For cells, optimizing fixation and permeabilization conditions

  • For Western blots, using gradient gels to better separate proteins of similar molecular weights

By systematically applying these approaches, researchers can significantly reduce non-specific binding and improve the specificity of MYH6 and MSH6 antibody applications in their experiments.

What controls should be included when using MYH6 or MSH6 antibodies in cancer research studies?

When using MYH6 or MSH6 antibodies in cancer research, a comprehensive set of controls should be included to ensure valid and interpretable results:

• Positive tissue controls:

  • For MSH6: Normal colonic mucosa or lymphocytes which reliably express MSH6

  • For MYH6: Normal cardiac tissue with known MYH6 expression

  • Cell lines with confirmed expression of the target protein

• Negative tissue controls:

  • MSH6-deficient tumor samples (e.g., MSH6-mutated endometrial or colorectal cancers)

  • Tissues known not to express MYH6 (e.g., liver)

  • Isogenic cell lines with CRISPR/Cas9 knockout of the target gene

• Molecular controls:

  • Correlation with MSH6 or MYH6 mRNA expression data

  • Comparison with genetic analysis of microsatellite instability status (for MSH6)

  • Multi-antibody validation using antibodies targeting different epitopes of the same protein

• Procedural controls:

  • No primary antibody controls to assess background from secondary reagents

  • Isotype control antibodies to evaluate non-specific binding

  • Peptide competition assays where the primary antibody is pre-incubated with excess antigen

• Biological context controls:

  • For MSH6, concurrent staining for MSH2 to evaluate the MutS alpha complex formation

  • Assessment of related DNA repair proteins or cardiac markers for biological context

  • Internal controls within each tissue section (stromal cells, infiltrating lymphocytes)

• Quantitative analysis controls:

  • Standardized positive controls for intensity calibration

  • Batch controls to account for inter-run variability

  • Digital image analysis with standardized algorithms for objective quantification

Implementing this comprehensive control strategy ensures that findings related to MYH6 or MSH6 expression in cancer research are robust, reproducible, and properly contextualized within the biological system being studied.

How should researchers interpret differences in antibody binding kinetics between different formats of the same antibody?

Interpreting differences in antibody binding kinetics between different formats (e.g., full IgG, Fab, scFv-Fc) or modified versions (e.g., humanized variants) requires careful consideration of multiple factors:

This sophisticated analysis of binding kinetics provides critical insights for selecting optimal antibody formats for specific research or therapeutic applications, as demonstrated by the superior performance of HuG6.3 in both binding and cytotoxicity assays .

What factors influence the selection of G6-id+ B cells in GTL mouse models for antibody immunodepletion studies?

GTL mouse models (humanized mice engrafted with human fetal bone marrow, liver, and thymus tissue) provide a valuable platform for studying antibody-mediated immunodepletion. When selecting G6-id+ B cells for such studies, several sophisticated factors must be considered:

• Engraftment efficiency assessment:
  The peripheral blood from GTL mice should be analyzed for human CD45+tm1wjl mononuclear cells to verify successful immune reconstitution. In the cited study, this verification was performed at 16 weeks post immune reconstruction before proceeding with antibody treatment .

• Selection of appropriate controls:
  GTL mice should be randomly assigned to treatment groups receiving the test antibody (e.g., MuG6) or control antibody to enable valid comparisons. This controls for variability in engraftment levels between individual mice .

• Timing of analysis:
  The immunodepletion effect should be evaluated at multiple timepoints. In the cited study, serum antibody levels were measured at days 7, 9, and 10, with levels of 12.4, 7.2, and 5.4 ng/ml respectively, showing the pharmacokinetics of the therapeutic antibody .

• B cell subpopulation analysis:
  While total B cell populations may remain unchanged, specific depletion of target subpopulations (G6-id+ B cells) must be carefully assessed. Flow cytometry enables quantification of these specific subpopulations .

• Functional outcome measures:
  Beyond cellular depletion, functional outcomes such as antibody production should be evaluated. The study demonstrated that expression of cognate IgM and IgG G6-id+ antibodies in plasma was markedly decreased in MuG6-treated mice at day 7 and remained low at day 21 .

• Pharmacokinetic considerations:
  Serum levels of the therapeutic antibody must be monitored to ensure they are sufficient for effect but below saturating levels. The study noted that day 7 serum MuG6 level (0.08 nM) was significantly below the equilibrium dissociation constant (KD) of MuG6, suggesting that observed effects were due to actual depletion rather than epitope masking .

These considerations enable robust evaluation of antibody-mediated immunodepletion in the GTL mouse model, providing critical preclinical data for potential therapeutic applications of antibodies like HuG6.3 in treating conditions such as B-cell chronic lymphocytic leukemia .